Abstracts Archive - Page 699 of 2425 - ACR Meeting Abstracts

Abstract Number: 1071 • ACR Convergence 2020
Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore
Choon Guan Chua¹, Jia Zhen Low¹ and Mona Manghani¹, ¹Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Anti-transcription intermediary factor 1-gamma autoantibody (anti-TIF-1ƴ Ab) associated dermatomyositis (DM) is strongly associated with the occurrence of malignancies. Patients may develop cancers prior to, concurrent…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
Abstract Number: 1076 • ACR Convergence 2020
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Lois Bolko¹, Kevin Didier², Jean-Hugues Salmon¹, Makoto Miyara³, Segolene Toquet², Amelie Servettaz², Yves Allenbach³, Olivier Benveniste⁴ and Baptiste Hervier⁵, ¹Maison Blanche Hospital, Reims, Champagne-Ardenne, France, ²Robert Debre Hospital, Reims, Champagne-Ardenne, France, ³Sorbonne Université, Paris, Ile-de-France, France, ⁴Sorbonne Université, paris, France, ⁵Saint-Louis Hospital, Paris, Ile-de-France, France
Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Dmitriy Cherny¹ and Carrie Richardson¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
Abstract Number: 1084 • ACR Convergence 2020
Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients
Didem Saygin¹, Bonny Rockette-Wagner², Chester Oddis³, Diane Koontz¹, Siamak Moghadam-Kia¹ and Rohit Aggarwal², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies are systemic inflammatory conditions characterized by muscle weakness and reduced muscle endurance that limit activities of daily living. Daily step count…
Abstract Number: 1079 • ACR Convergence 2020
Sex Differences in Antibody Profile, Phenotype, and Treatment Response in a Racially Diverse Population with Idiopathic Inflammatory Myopathies
Ana Valle¹, Jammie Law², Katherine Mullins³ and Shereen Mahmood⁴, ¹Albert Einstein College of Medicine, New York, NY, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: It is established that autoimmune diseases are more common in females than males. Large scale idiopathic inflammatory myopathy (IIM) registries have shown a similar…
Abstract Number: 1074 • ACR Convergence 2020
A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine
Karel Venne¹, Valérie Leclair², Julie D'Aoust¹, Océane Landon-Cardinal³, Alexandra Albert⁴, Julie Beauchemin⁵, Denis Brunet⁶, Lucie Roy⁷, Benjamin Ellezam⁸, Jason Karamchandani⁹, Rami Massie¹⁰, Erin O'Ferrall¹⁰, Alain Meyer¹¹, Yves Troyanov¹², Minoru Satoh¹³, Marvin Fritzler¹⁴ and Marie Hudson², ¹Division of Rheumatology, Rheumatology Fellow, McGill University,, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁵Division of Rheumatology, Hôpital Charles-Lemoyne, Longueuil, QC, Canada, ⁶Division of Neurology, Centre Hospitalier de l’Université Laval, Quebec, QC, Canada, ⁷Division of Rheumatology, CIUSSS du Saguenay Lac-Saint-Jean, Saguenay, Canada, ⁸Division of Pathology, CHU Sainte-Justine, Montreal, QC, Canada, ⁹Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹⁰Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹¹Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ¹³Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc). There is a paucity of data on scleromyositis…
Abstract Number: 1087 • ACR Convergence 2020
Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
Yubin Li¹, Christina Bax², Jay Patel³, Adarsh Ravishankar³, Krisha Desai⁴, Majid Zeidi⁴, Muhammad Bashir⁴ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid…
Abstract Number: 1090 • ACR Convergence 2020
Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease
Sangmee Bae¹, Jennifer Wang¹, Ani Shahbazian² and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with dermatomyositis (DM) and polymyositis (PM). We previously reported abnormal anti-oxidant function…
Abstract Number: 1091 • ACR Convergence 2020
A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD
Sangmee Bae¹, Andrea Oh², Grace Kim³, Jonathan Goldin³ and Christina Charles-Schoeman⁴, ¹University of California Los Angeles, Los Angeles, CA, ²National Jewish Health, Denver, CO, ³University of California, Los Angeles, Los Angeles, ⁴University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
Abstract Number: 1086 • ACR Convergence 2020
The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases
Sarah El Chami¹, Christopher Williams¹, Ghaith Noaiseh¹, Amrita Bath¹ and Duaa Jabari¹, ¹The University of Kansas Health System, Kansas city, KS
Background/Purpose: Myositis-specific antibodies (MSA) are thought to be highly specific in patients with idiopathic inflammatory myopathies.[1] However, in clinical practice these antibodies are frequently found…
Abstract Number: 1097 • ACR Convergence 2020
Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies
Hector Culebro¹, Jose Torres-Ruiz², Fabiola Cassiano Quezada¹ and Alfredo Perez Fragoso¹, ¹INCMNSZ, MEXICO, Mexico, ²NIAMS, National Institute of Health, Bethesda
Background/Purpose: Myeloid derived suppressor cells (MDSCs) including their granulocyte (Gr-MDSCs) and monocyte (Mo-MDSCs) subtypes constitute a cellular subset with potent immune regulatory capacity. An augmented…
Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Julie Paik¹, Jemima Albayda¹, Eleni Tiniakou¹, Grazyna Purwin¹, Andrew Koenig² and Lisa Christopher-Stine¹, ¹Johns Hopkins University, Baltimore, MD, ²Pfizer Inc, New York City, NY
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
Abstract Number: 1089 • ACR Convergence 2020
Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
Jorge Gamboa¹, Daniel Carranza Leon¹, Rachelle Crescenzi¹, Adriana Marton², Annette Oeser¹, Cecilia Chung¹, Jens Titze², Michelle Ormseth¹ and C. Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke NUS Medical School, Singapore, Singapore
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have reduced physical activity and frequently complain of fatigue. Exercise reduces fatigue in patients with SLE; however, the…
Abstract Number: 0981 • ACR Convergence 2020
Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
Milena Gianfrancesco¹, Maria Dall'Era², Louise Murphy³, Charles Helmick³, Jing Li¹, Stephanie Rush¹, Laura Trupin¹ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴UCSF, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Contemporary data indicate that minority populations are at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].